1. Engineered Peptide Macrocycles Can Inhibit Matrix Metalloproteinases with High Selectivity
- Author
-
Christian Heinis, Xu-Dong Kong, Khan Maola, Jeremy Touati, Jonas Wilbs, Alice Baumann, Kaycie Deyle, and Michal Sabisz
- Subjects
Phage display ,Peptide ,Matrix Metalloproteinase Inhibitors ,Matrix metalloproteinase ,Protein Engineering ,010402 general chemistry ,01 natural sciences ,Catalysis ,Substrate Specificity ,Peptide Library ,In vivo ,Catalytic Domain ,Humans ,Chelation ,Amino Acid Sequence ,Binding site ,chemistry.chemical_classification ,Binding Sites ,Sequence Homology, Amino Acid ,010405 organic chemistry ,Rational design ,Substrate (chemistry) ,General Chemistry ,General Medicine ,Peptide Fragments ,0104 chemical sciences ,chemistry ,Biochemistry ,Proteolysis ,Matrix Metalloproteinase 2 - Abstract
Matrix metalloproteinases (MMPs) are zinc-dependent endopeptidases at the intersection of health and disease due to their involvement in processes such as tissue repair and immunity as well as cancer and inflammation. Because of the high structural conservation in the catalytic domains and shallow substrate binding sites, selective, small-molecule inhibitors of MMPs have remained elusive. In a tour-de-force peptide engineering approach combining phage-display selections, rational design of enhanced zinc chelation, and d-amino acid screening, we succeeded in developing a first synthetic MMP-2 inhibitor that combines high potency (Ki =1.9±0.5 nm), high target selectivity, and proteolytic stability, and thus fulfills all the required qualities for in cell culture and in vivo application. Our work suggests that selective MMP inhibition is achievable with peptide macrocycles and paves the way for developing specific inhibitors for application as chemical probes and potentially therapeutics.
- Published
- 2019
- Full Text
- View/download PDF